

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A method comprising transplantation of insulin producing cells in the form of isolating islets to a patient suffering from insulin dependent diabetes mellitus (IDDM),
 wherein said isolated islets are ~~coated~~modified by irreversible adsorption with a clotting preventing agent,
 with the proviso that the isolated islets are not artificially encapsulated,
 whereby said clotting preventing agent acts to prevent or reduce clotting.

2. (previously presented) The method according to claim 1, wherein the preventing agent is an anticoagulant.

3. (previously presented) The method according to claim 2, wherein the anticoagulant is heparin or fractions or derivatives thereof.

4. (previously presented) The method according to claim 3, wherein islet cells are coated with heparin or fractions or derivatives thereof by preincubation of islets in

a solution containing heparin or fractions or derivatives thereof.

5. (previously presented) The method according to claim 1, wherein the preventing agent is an inhibitor of platelet activation.

6. (previously presented) The method according to claim 5, wherein the preventing agent is a RGD containing peptide or a monoclonal antibody which inhibits the interaction of platelet integrins with their specific ligands.

7. (previously presented) The method according to claim 5, wherein the preventing agent is a monoclonal antibody or a peptide directed against the Fc receptor on platelets.

8. (previously presented) The method according to any one of the claims 1-7, wherein more than one clotting preventing agent is used.

9. (previously presented) The method according to any one of the claims 1-7, wherein the preventing agent is supplemented by an inhibitor of complement.

10. (currently amended) A method for coating isolated cells, comprising

coating islets of Langerhans cells with a heparin
conjugate on the islet surface, with the proviso that the
cells are not artificially encapsulated,
 whereby clotting is reduced or prevented.

11. (previously presented) A method for increasing
survival of islet cells in connection with transplantation of
insulin producing cells to patients with insulin dependent
diabetes mellitus (IDDM), comprising prevention of clotting,
monitored as reduced generation of thrombin-antithrombin
complex (TAT complex).